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Abstract
I In nt tr ro od du uc ct ti io on n: :   Hypoadiponectinaemia is an important risk factor for non-alcoholic
fatty liver disease (NAFLD). However, little is known about its role in the Chinese
population. This study sought to assess the prevalence of NAFLD and its
association with hypoadiponectinaemia in middle-aged and elderly Chinese. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   We conducted a population-based cross-sectional study
in an urban Shanghai sample of 2201 participants age 50 years to 83 years 
(973 men, 1228 women). Hepatic ultrasonographic examination was performed
for all participants. Serum adiponectin concentrations were measured by ELISA
methods. 
R Re es su ul lt ts s: :   The prevalence of NAFLD was 19.8% (16.0% in men, 22.8% in women).
Serum adiponectin levels were significantly higher in female than in male
subjects (p < 0.001). Serum adiponectin levels were significantly lower in NAFLD
subjects than those in control subjects (p < 0.001). The prevalence of NAFLD
progressively increased with declining adiponectin levels (pfor trend < 0.001). The
participants in the lowest adiponectin quartile had a significantly increased risk
for acquiring NAFLD (OR = 2.31, 95% CI 1.72-3.15) after adjustment for potential
confounders.
C Co on nc cl lu us si io on ns s: :   Population-based screening suggests that NAFLD is highly prevalent
in middle-aged and elderly people in Shanghai, particularly among women.
Serum adiponectin level is negatively associated with NAFLD independently of
potential cofounders, indicating that hypoadiponectinaemia may contribute to
the development of NAFLD.
K Ke ey y   w wo or rd ds s: :   non-alcoholic fatty liver disease, prevalence, risk factor, hypoadipo  -
nectinaemia.
Introduction
During the past two decades, China has experienced rapid economic
growth and aging of its population. Resulting changes in lifestyle and
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longer life expectancy have led to an increased
burden of cardiovascular and other chronic diseases
[1, 2]. Non-alcoholic fatty liver disease (NAFLD) is
a clinicopathological entity which is characterized
by the presence of fat droplets in the hepatocytes
in the absence of alcohol consumption, representing
a spectrum of hepatic injuries, ranging from pure
fatty  infiltration  (steatosis)  to  inflammation 
(non-alcoholic steatohepatitis [NASH]), fibrosis, 
and cirrhosis [3, 4]. Non-alcoholic fatty liver disease
is  the  most  common  chronic  liver  condition
worldwide, affecting approximately 20% of the
general population, with increasing prevalence [5],
and paralleling the increasing prevalence of obesity
[6], type 2 diabetes [7], metabolic syndrome [8] and
cardiovascular disease (CVD) [9]. Non-alcoholic fatty
liver disease is now receiving greater attention and
is regarded as a public health issue. Therefore,
managing NAFLD is crucial to the prevention of CVD
and metabolism-related diseases. 
Adiponectin is an adipocyte-derived cytokine
known  to  mediate  insulin  action  [10].  Hypo  -
adiponec    tinaemia has been demonstrated to be
linked with insulin resistance, while increased
adiponectin levels by supplementation of adipo  -
nectin  attenuated  the  insulin  resistance  [11].
A specific role for adiponectin in the liver has also
been  suggested.  Adiponectin  levels  correlate
inversely  with  hepatic  fat  and  hepatic  insulin
resistance in diabetic patients [12], whereas in
healthy  subjects,  low  adiponectin  levels  are
significantly  associated  with  increased  serum
concentration of alanine transaminase (ALT) and 
ʳ-glutamyl transpeptidase, suggesting a possible
contribution of adiponectin in maintaining liver
integrity  [13,  14].  Moreover,  adiponectin  also
manifests anti-inflammatory action by neutralizing
tumour necrosis factor-α (TNF-α) [15] and anti-
fibrotic action by inhibiting hepatic stellate cell
proliferation and migration [16]. 
The mechanisms behind the hepato-protective
properties of adiponectin have been extensively
studied. In the NAFLD mouse model, adiponectin
has anti-inflammatory and insulin-reducing effects,
and improves the pathological condition of NAFLD
[17].  Recently  a study  indicated  that  adipo  -
nectin/AdipoR2 signalling in hepatocytes regulated
steatohepatitis progression by changing PPAR-α
activity and ROS accumulation, a process in which
TGF-β signalling is implicated [18]. AdipoR2 is
expressed predominantly in the liver; decreased
expression of AdipoR2 in the livers of patients with
NASH has been reported [19], suggesting that
adiponectin signalling might play an important role
in the pathogenesis of NAFLD.
Few studies have published information on the
prevalence of NAFLD in Chinese populations [20,
21]. There is increasing evidence indicating the close
association between circulating adiponectin levels
and NAFLD in different ethnic groups such as
Caucasian [22, 23], Japanese [24] and Korean [25].
However, data about the role of adiponectin with
regards to NAFLD in the Chinese population are
limited. 
Therefore, this study intended to determine the
prevalence of NAFLD and to examine the relation
between NAFLD and serum adiponectin levels in
a population-based survey of middle-aged and
elderly Chinese people in Shanghai, China.
Material and methods
S Su ub bj je ec ct ts s
In 2007, China launched a Study on Metabolic
Syndrome of Aging Population in China, a popu  -
lation-based cross-sectional study, designed to
evaluate the prevalence of metabolic syndrome,
and other age-related chronic diseases. All studied
individuals come from Simenerlu Community of
Jingan District and Jiangninglu Community of Putuo
District in Shanghai, China. A multistage stratified
cluster  sampling  method  was  used  to  select
subjects from these two communities. Only one
participant (≥ 50 years) was randomly selected from
each  household  without  any  of  the  following
conditions: severe psychological disorders, physical
disabilities, cancers, senile dementia or currently
diagnosed with tuberculosis, acquired immune
deficiency syndrome, clinical signs or symptoms of
inborn errors of metabolism, a history of use of
toxins or drugs associated with liver steatosis or
any other communicable disease. Elevated liver
enzymes  (serum  alanine  transaminase  [ALT],
aspartate aminotransferase [AST] and ʳ-glutamyl
transferase [GGT]) were not an exclusion criterion.
Fatty liver patients consuming more than 20 g of
alcohol  per  day  were  excluded.  This  study  is
a population-based study. In our study subjects, the
controls just non-NAFLD subjects.
A total of 2,219 subjects (986 men, 1,233 women)
completed the survey. Altogether 454 subjects
(NAFLD group) were diagnosed with fatty liver by
ultrasound examination in this study. A total of 
18 individuals were excluded from analysis due to
alcohol consumption ≥ 20 g/day. Written informed
consent was obtained from all the participants. The
study was approved by the Institutional Review
Broad of Huashan Hospital.
D Da at ta a   c co ol ll le ec ct ti io on n   
A standardized  questionnaire  was  used  by
trained physicians to collect information such as
age, sex, smoking (yes/no), alcohol drinking, and
medication use. Physical activity level was classified
as  low,  moderate,  or  high  according  to  the
International Physical Activity Questionnaire scoringArch Med Sci 4, August / 2011 667
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protocol. All subjects were assessed after overnight
fasting for at least 10 h. Detailed anthropometric
measurements including height, weight, waist
circumference,  hip  circumference  and  blood
pressure were carried out by trained physicians.
Height was measured in metres (without shoes),
and  weight  in  kilograms  (with  heavy  clothing
removed  and  1 kg  deducted  for  remaining
garments). Body mass index (BMI) was calculated
as weight in kilograms divided by the square of
height in metres. We measured waist circumference
in standing subjects with a soft tape midway
between the lowest rib and the iliac crest. Hip
circumference was measured over the widest part
of the gluteal region, and the waist-to-hip ratio was
calculated as a measure of central obesity. Two
blood pressure recordings were obtained from the
right arm of patients in a sitting position after 
30 min of rest; measurements were taken in 5-min
intervals, and mean values were calculated.
L La ab bo or ra at to or ry y   m me ea as su ur re em me en nt ts s
Peripheral venous blood samples were collected
in tubes containing liquid EDTA, centrifuged at 4°C,
10  min,  3000  rpm  and  stored  at  –80°C  until
analysis. The fasting glucose, glucose 2 h after oral
glucose tolerance test (OGTT), total cholesterol,
triglycerides, LDL cholesterol and HDL cholesterol
were measured enzymatically on an automatic
analyser  (Hitachi  7080).  Levels  of  aspartate
aminotransferase (AST) and alanine amino  trans  -
ferase (ALT) were measured by the UV method. 
ʳ-Glutamyltransferase (GGT) was measured by 
the Szasz-Persijn method. Fasting insulin was
determined by radioimmunoassay (Linco Research,
St. Charles, USA). Insulin resistance was estimated
using homeostasis model assessment index-insulin
resistance (HOMA-IR). 
The serum CRP and adiponectin were deter  -
mined in duplicate by ELISA with a Duoset kit (R&D
Systems, Minneapolis, USA) as recommended by
the manufacturer. The ELISA system had an intra-
assay coefficient of variation of 3-7% and an inter-
assay coefficient of variation of 4-9%.
D Di ia ag gn no os si is s   o of f   n no on n- -a al lc co oh ho ol li ic c   f fa at tt ty y   l li iv ve er r   d di is se ea as se e
Ultrasound examinations were performed by
a single examiner using a Siemens Versa Plus
(Siemens,  Munich,  Germany)  equipped  with 
a 3.5-MHz convex-array probe and a 9-MHz linear-
array probe. Scans were performed after a fasting
period of at least 5 h. All subjects received hepatic
ultrasound scanning. According to established
diagnostic criteria [26-28], the degree of fatty
infiltration of the liver was classified as “mild”
(hepatic steatosis grade I), “moderate” (hepatic
steatosis grade II), or “severe” (hepatic steatosis
grade III). Biopsy studies in adults demonstrate that
ultrasonography has a high sensitivity (89%) and
specificity (93%) for the detection and classification
of hepatic steatosis [27], and the correlation with
microscopic fat content in macrovesicular steatosis
is good compared to the correlation achieved by
hepatic fat quantification with magnetic resonance
imaging (MRI) (r = 0.90, p < 0.001) [29].
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Normally distributed data were expressed as
means ± SD, whereas variables with a skewed
distribution were reported as median (interquartile
range)  and  log  transformed  to  approximate
normality before analysis. Categorical variables were
represented by frequency and percentage. Analysis
of covariance for continuous variables and ˇ2 test
for  categorical  variables  were  applied  for  the
comparison.  Correlation  coefficients  between
adiponectin and metabolic features were calculated
by simple and partial correlation analysis on ranks
(Spearman correlation). Factors’ scores were used
in  multivariate  logistic  regression  analysis  to
determine the factors that were significantly related
to hepatic steatosis, using the presence of hepatic
steatosis as a dependent variable, and adiponectin,
age, BMI, C-reactive protein (CRP), waist circum  -
ference, and homeostatic model assessment of
insulin  resistance  (HOMA-IR)  as  independent
variables. Multivariate logistic regression models
were used to estimate the odds ratios (ORs) for
hepatic steatosis. Potential confounding variables
including age, gender, smoking, physical activity,
CRP, adiponectin, HOMA-IR, BMI, waist circum  -
ference, and waist to hip ratio were controlled in
the regression models. When appropriate, natural
log-transformed values were used for the analyses.
All statistical analysis were performed with the
SPSS Statistical Package (version 13.0; SPSS Inc.,
Chicago, IL). Value of p < 0.05 was considered
statistically significant.
Results
A An nt th hr ro op po om me et tr ri ic c, ,   c cl li in ni ic ca al l, ,   a an nd d   l la ab bo or ra at to or ry y   d da at ta a
Clinical and biochemical variables of the patients
included in the study are summarized in Table I. The
NAFLD  subjects  have  higher  age,  BMI,  waist
circumference, waist to hip ratio, smoking, systolic
bood pressure (SBP), diastolic blood pressure (DBP),
fasting plasma glucose, fasting plasma insulin,
HOMA-IR, CRP, ALT, AST, GGT, triglyceride and total
cholesterol  than  those  of  control  subjects 
(all p < 0.05). In contrast, the control subjects have
higher physical activity and HDL cholesterol (all 
p < 0.001).
Adiponectin levels ranged from 0.230 µg/ml to
51.740 µg/ml in the study population. The median668 Arch Med Sci 4, August / 2011
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adiponectin concentration in women was signifi  -
cantly higher than that in men (p < 0.001) (Table II).
In addition, adiponectin levels in subjects older
than 70 years were significantly higher than those
in subjects in their fifties and sixties (p < 0.001) 
(Table II). Adiponectin levels were significantly
lower in NAFLD patients (Figure 1). In relation to
gender, adiponectin concentrations were systema  -
tically  lower  in  men,  both  in  NAFLD  and  in
controls. 
A Ad di ip po on ne ec ct ti in n   l le ev ve el ls s   i in n   r re el la at ti io on n   t to o   c cl li in ni ic ca al l, ,
a an nt th hr ro op po om me et tr ri ic c, ,   a an nd d   b bi io oc ch he em mi ic ca al l   p pa ar ra am me et te er rs s
Adiponectin was significantly correlated with
several clinical, anthropometric and biochemical
variables in the total studied population (Table III).
In particular, adiponectin was strongly negatively
associated with central adiposity, insulin resistance,
and  hyperlipidaemia.  Adiponectin  levels  also
C Ch ha ar ra ac ct te er ri is st ti ic cs s N NA AF FL LD D C Co on nt tr ro ol l V Va al lu ue e   o of f   p p
N 436 1765 –
Age [year] 61.1 ±8.3 59.6 ±8.2 < 0.001
BMI [kg/m2] 26.6 ±3.0 24.5 ±3.2 < 0.001
Waist circumference [cm] 88.6 ±8.2 82.3 ±9.0 < 0.001
Waist to hip ratio 0.89 ±0.07 0.86 ±0.07 < 0.001
Smoking (yes) 82 (18.8) 196 (11.1) < 0.001
Physical activity: < 0.001
Low 170 (39.0) 120 (6.8)
Moderate 228 (52.3) 1234 (69.9)
High 38 (8.7) 411 (23.3)
SBP [mmHg] 133.4 ±17.1 127.7 ±17.5 < 0.001
DBP [mmHg] 84.0 ±10.3 80.8 ±17.6 0.003
Fasting plasma glucose [mmol/l] 5.9 ±1.3 5.6 ±1.3 0.002
Fasting plasma insulin [µU/ml]e 9.08 (6.05-13.70) 6.59 (4.45-9.68) < 0.001
HOMA-IRe 2.30 (1.46-3.70) 1.59 (1.01-2.39) < 0.001
CRP [µg/ml] 6.3 ±4.9 4.4 ±4.1 < 0.001
Adiponectin [µg/ml]e 7.73 (5.43-10.63) 9.65 (6.77-13.36) < 0.001
ALT [U/l] 35.3 ±16.8 24.4 ±14.6 < 0.001
AST [U/l] 29.7 ±5.1 21.5 ±4.8 < 0.001
GGT [U/l] 33.7 ±10.4 13.1 ±7.7 < 0.001
Triglycerides [mmol/l]e 2.3 ±1.7 1.6 ±1.3 < 0.001
Total cholesterol [mmol/l] 5.5 ±1.1 5.4 ±1.0 0.108
LDL-c [mmol/l] 3.2 ±0.8 3.2 ±0.8 0.968
HDL-c [mmol/l] 1.2 ±0.3 1.4 ±0.5 < 0.001
BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, CRP – C-reactive protein, ALT – alanine aminotransferase,
AST – aspartate aminotransferase, GGT – ʳ-glutamyltransferase, LDL-c – low-density lipoprotein cholesterol, HDL-c – high-density lipoprotein
cholesterol, HOMA-IR – homeostasis model of assessment-insulin resistance, ethese variables were log transformed before analysis
T Ta ab bl le e   I I. . Baseline characteristics of NAFLD and control subjects
S Su ub bg gr ro ou up p N Nu um mb be er r A Ad di ip po on ne ec ct ti in n    N NA AF FL LD D   
[ [µ µg g/ /m ml l] ]* * p pr re ev va al le en nc ce e   [ [% %] ]
Gender
Male 973 7.79 (5.38-11.13) 16.03
Female 1228 9.95 (7.23-13.93) 22.80
Value of p < 0.001 < 0.001
Age group 
[years]
50-59 1159 8.81 (5.99-12.31) 17.00
60-69 691 10.26 (7.74-13.99) 24.31
≥ 70 351 12.27 (8.41-15.78) 20.22
Value of p < 0.001 0.001
*data expressed as median (interquartile range)
T Ta ab bl le e   I II I. . Distribution of adiponectin and nonalcoholic
fatty liver disease prevalence by gender and ageArch Med Sci 4, August / 2011 669
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decreased with increasing prevalence of NAFLD 
(p for trend < 0.001) (Figure 2). 
P Pr re ev va al le en nc ce e   o of f   n no on n- -a al lc co oh ho ol li ic c   f fa at tt ty y   l li iv ve er r   d di is se ea as se e
Hepatic steatosis was diagnosed by ultrasound
in  19.8%  of  the  subjects.  Most  subjects  were
affected by mild to moderate fatty infiltration of the
liver (hepatic steatosis grade I to II) (the proportions
of  hepatic  steatosis  in  total  subjects  were 
14.4%, 4.0% and 1.3%, respectively). We observed 
a clear gender difference in prevalence rates, with
significantly  more  females  affected  by  NAFLD 
(Table II). Interestingly, prevalence of NAFLD in
subjects aged 60-69 years (24.31%) was signifi  -
cantly higher than in subjects in their fifties (17.0%)
and  in  subjects  older  than  70  years  (20.22%) 
(p < 0.001).
A As ss so oc ci ia at ti io on n   b be et tw we ee en n   a ad di ip po on ne ec ct ti in n   l le ev ve el ls s   
a an nd d   n no on n- -a al lc co oh ho ol li ic c   f fa at tt ty y   l li iv ve er r   d di is se ea as se e
In multivariate logistic regression analysis the
presence of NAFLD was used as the dependent
variable, while all other variables were designated
the independent variables. Age, BMI, serum CRP
level, waist circumference, HOMA-IR and serum
adiponectin  level  were  independent  factors
significantly associated with NAFLD. The odds ratios
(OR) were calculated for NAFLD with female sex 
(OR = 1.43, 95% confidence interval [CI]: 1.11-1.94),
age (OR = 1.29, 95% CI: 1.05-1.68), BMI (OR = 1.18,
95% CI: 1.09-1.31), CRP (OR = 1.20, 95% CI: 1.02-1.43),
waist circumference (OR = 1.12, 95% CI: 1.02-1.30),
HOMA-IR (OR = 2.56, 95% CI: 1.19-5.62), adiponectin
(OR = 0.45, 95% CI: 0.17-0.81).
Table  IV  displays  the  ORs  for  NAFLD  by
adiponectin quartiles. As expected, decreased ORs
for NAFLD were observed from the 1st to the 4th
adiponectin quartiles in all subgroups: male and
female (p for trend < 0.001 for all) after adjustment
for  smoking,  physical  activity,  SBP,  DBP,  CRP,
triglycerides, HOMA-IR, BMI. 
Discussion
The  findings  of  our  study  reinforce  the
observation  that  NAFLD  is  highly  prevalent  in
middle-aged and elderly subjects, with a clear
female predominance in the study population.
Furthermore, we further investigated the rela  -
tionship of NAFLD and serum adiponectin. To our
best  knowledge,  this  is  the  first  large-scale
population-based study investigating the asso  -
ciation of adiponectin with NAFLD in middle-aged
V Va ar ri ia ab bl le e C Cr ru ud de e   r r P Pa ar rt ti ia al l   r r† †
Age [year] 0.18**
BMI [kg/m2] –0.20** –0.21**
Waist circumference [cm] –0.20** –0.19**
SBP [mmHg] –0.08* –0.12**
DBP [mmHg] –0.09* –0.07*
ALT [U/l] –0.14** –0.10**
AST [U/l] –0.12** –0.09*
GGT [U/l] 0.11** –0.07*
Total cholesterol [mmol/l] 0.11** 0.04
Triglycerides [mmol/l] –0.12** –0.11**
HDL-c [mmol/l] 0.24** 0.20**
CRP [µg/ml] –0.03 –0.02
Fasting plasma glucose [mmol/l]) –0.11** –0.11**
Fasting insulin [µU/ml] –0.23** –0.24**
HOMA-IR –0.20** –0.21**
abbrevaitions – see Table I, *p < 0.05, **p < 0.001, †adjusted for age, sex
T Ta ab bl le e   I II II I. .   Crude and partial correlation between serum
adiponectin and clinical parameters in the study
subjects
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and elderly Chinese. A strong inverse association
was found between adiponectin levels and NAFLD,
independent of well-known NAFLD risk factors.
Hypoadiponectinaemia,  as  indicated  in  other
population studies, is also an important risk factor
associated with NAFLD risk in the Chinese po  -
pulation.
The overall prevalence of fatty liver of 19.8% in
our study cohort is notably lower than reported
prevalence rates for the middle-aged and elderly
population from other studies of China (24.8% in
Shanghai and 25.7% in Guangzhou) [20, 21]. The
discrepancy among the studies is probably due to
the methods of sample selection, modalities used
for diagnosis and diversity of life styles and dietary
habits  in  different  areas.  The  clear  female
predominance in NAFLD found in our study has
been demonstrated before in most published case
series and in a population-based study [20, 21]. Our
data suggest a distinctive prevalence pattern of
NAFLD  dependent  on  gender  similar  to  the
prevalence rates reported previously in studies [20,
21]. Given that our study is a random cluster-
selected  sample  with  a relatively  low  bias  by
a sampling error, and taking into account the
previously published results, it could also reflect the
prevalence of distinct histological patterns of liver
injury and possibly gender-specific role of sex
steroids in the pathogenesis of NAFLD. 
To investigate predictors of NAFLD, we chose
factor analysis to reduce the number of available
variables to a more manageable number of factors,
each of which represents a linear combination of
related variables. Therefore, factor analysis provides
insight  into  the  complex  interrelationships  of
commonly  investigated  anthropometric  and
metabolic  parameters  and  furthermore  allows
weighing the association of each complex factors
with the phenotype of NAFLD when used in further
analysis. Our analysis identified six factors in the set
of investigated parameters – age, BMI, CRP, waist
circumference,  HOMA-IR  and  adiponectin  –
suggesting that age, low-grade systemic inflam  -
mation, visceral fat, insulin resistance and adipokine
could play a causal role in the development of NAFLD. 
Adiponectin has anti-inflammatory properties in
the liver, and its deficiency might account for high
aminotransferase and liver disease progression. In
KK Ay-obese mice treated by lipopolysaccharide,
pre-treatment with adiponectin reduces mortality,
aminotransferase elevation, and the amount of
apoptosis  [30].  A direct  anti-fibrotic  effect  of
adiponectin has been suggested on the basis of
adiponectin receptor gene expression in hepatic
stellate cells and the inhibition of stellate cell
proliferation  and  migration  after  adiponectin
treatment [16]. Some studies have demonstrated
that  adiponectin  deficiency  correlated  with
increased liver fat [31-24], suggesting that adipo  -
nectin could be the critical factor regulating liver fat
content. Furthermore, adiponectin has recently been
shown to alleviate NAFLD in mice by increasing
N NA AF FL LD D O OR Rs s   ( (9 95 5% %   C CI I) )
Q Q1 1 Q Q2 2 Q Q3 3 Q Q4 4
Total
Model 1* 2.72 (1.84-4.12) 1.45 (1.11-1.82) 1.17 (0.89-1.48) 1
Model 2† 2.64 (1.90-3.63) 1.42 (1.07-1.95) 1.15 (0.86-1.47) 1
Model 3‡ 2.45 (1.80-3.37) 1.40 (1.05-1.92) 1.12 (0.85-1.43) 1
Model 4ʶ 2.34 (1.74-3.16) 1.37 (1.02-1.88) 1.09 (0.81-1.45) 1
Women
Model 1* 3.03 (2.03-4.62) 1.83 (1.51-2.35) 1.29 (0.74-2.12) 1
Model 2† 2.89 (1.99-4.23) 1.72 (1.29-2.38) 1.25 (0.83-1.88) 1
Model 3‡ 2.73 (1.84-4.13) 1.65 (1.31-2.44) 1.23 (0.79-1.82) 1
Model 4ʶ 2.61 (1.91-3.73) 1.59 (1.24-2.35) 1.18 (0.83-1.71) 1
Men
Model 1* 2.59 (1.70-3.97) 1.39 (1.03-1.97) 1.11 (0.84-1.49) 1
Model 2† 2.54 (1.73-3.77) 1.27 (0.83-1.88) 1.09 (0.81-1.47) 1
Model 3‡ 2.32 (1.50-3.93) 1.22 (0.84-1.79) 1.08 (0.82-1.43) 1
Model 4ʶ 2.24 (1.51-3.42) 1.18 (0.79-1.81) 1.04 (0.77-1.41) 1
*Model 1 adjusted for age, in total group, model 1 adjusted for age and gender, †model 2 further adjusted for smoking, physical activity, 
SBP and DBP, ‡model 3 further adjusted for CRP, triglycerides and HOMA-IR, ʶmodel 4 further adjusted for BMI
T Ta ab bl le e   I IV V. .   Adjusted ORs and 95% CIs for non-alcoholic fatty liver disease according to adiponectin quartiles (with Q4
as reference)Arch Med Sci 4, August / 2011 671
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carnitine palmitoyltransferase-1 activity and hepatic
fat oxidation, and by suppressing TNF-α production
in the liver and in plasma [16]. 
As in our present study, previous studies in
different populations uniformly reported strong
associations between hypoadiponectinaemia and
the development of NAFLD by different imaging
methods or histopathological correlates [35, 36].
However, there are very few population-based
studies. Here we also demonstrate that increases
in  the  degree  of  fatty  infiltration  of  the  liver,
assessed according to established (and in the
clinical setting readily available) ultrasound criteria,
are associated with gradually decreasing serum
adiponectin  levels  independent  of  potential
confounders in a large-scale population. 
In conclusion, our study indicates that NAFLD is
highly prevalent in the middle-aged and elderly
Chinese people living in urban Shanghai, especially
among women. Developing effective public health
strategies  for  the  prevention,  detection,  and
treatment of NAFLD should be an urgent priority to
reduce the social and medical burden of NAFLD and
its related metabolic abnormalities in China. We
also  found  a close  relation  between  serum
adiponectin concentrations and NAFLD among the
middle-aged  and  elderly  Chinese,  suggesting
a potential role of adiponectin in the pathogenesis
of NAFLD in middle-aged and elderly subjects.
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